JJ
J&J and Google partner to build surgical robots
March 30, 2015Medical Communications, Sales and Marketing Biogen, Ethicon, J&J, JJ, Johnson and Johnson, MS, google, robots
The medical device subsidiary of Johnson & Johnson Ethicon is to collaborate with Google to build surgical robots and perform …
J&J blood cancer drug gets UK launch
March 25, 2015Sales and Marketing Cancer, J&J, JJ, Janssen, NICE, Velcade, bortezomib, mcl, nhl
Johnson and Johnson’s pharma unit Janssen is launching Velcade in the UK for the first-line treatment of Mantle Cell Lymphoma …
J&J acquires Index Ventures-owned firm XO1
March 23, 2015Sales and Marketing Index Ventures, Isis, J&J, JJ, Janssen, vectura, xo1
Johnson & Johnson’s pharma unit Janssen has acquired Index Ventures’ biopharma firm XO1 Limited that develops the promising anti-thrombin antibody …
Big pharma partners with government over $100m dementia fund
March 17, 2015Research and Development, Sales and Marketing Alzheimer's, Biogen IDEC, GSK, J&J, JJ, Pfizer, government, jp morgan, lilly
Lilly, Pfizer, GSK, J&J and Biogen Idec are set to join a $100m Dementia Discovery Fund to boost research into …
J&J pleads guilty over children’s contaminated medicine
March 12, 2015Manufacturing and Production, Sales and Marketing FDA, J&J, JJ, McNeil, OTC, Tylenol, consta, hamburg, recall
Johnson & Johnson’s consumer division McNeil has pleaded guilty and will pay fines of $25 million for wrongdoings regarding its …
J&J leukaemia drug gets FDA go-ahead
January 30, 2015Sales and Marketing FDA, J&J, JJ, Janssen, The US Food and Drug Administration has shown Janssen’s leukaemia drug Imbruvica the green light to treat patients with waldenström’s macroglobulinemia (WM) – a rare indol, Waldenström’s Macroglobulinemia, ibrutinab, imbruvica, johnson
The US Food and Drug Administration has shown Janssen’s leukaemia drug Imbruvica the green light to treat patients with waldenström’s …
Scientists warn Ebola virus is mutating
January 29, 2015Research and Development, Sales and Marketing Africa, Ebola, GAVI, GSK, Institut Pasteur, J&J, JJ, guinea
Researchers in France studying the Ebola epidemic say the virus has mutated making it potentially even more contagious. Scientists based …
NICE recommends Bayer heart attack drug
January 26, 2015Sales and Marketing ACS, Bayer, J&J, JJ, NICE, Xarelto, q4, rivaroxaban
NICE has recommended Xarelto in final draft guidance as an option for preventing blood clots in people who have had …
Olysio and Xarelto boost J&J’s Q4
January 21, 2015Sales and Marketing J&J, JJ, Janssen, NICE, Remicade, Velcade, Xarelto, financials, hep C, olysio, q4, quarter four
Johnson & Johnson earned a 10% increase in worldwide sales of its drugs in the last quarter of 2014 compared …
Isis and J&J sign RNA deal
January 8, 2015Research and Development, Sales and Marketing Isis, J&J, JJ, Janssen, RNA, gastrointestinal tract
Isis Pharmaceuticals is collaborating with Johnson & Johnson’s pharma unit Janssen to develop antisense drugs to treat autoimmune disorders. The …
Vectura and J&J shake on asthma/COPD deal
January 6, 2015Research and Development, Sales and Marketing COPD, J&J, JJ, Janssen, asthma, johnson, rezolsta, tybost, vectura
British firm Vectura has entered an agreement with Johnson & Johnson’s pharma unit Janssen to develop therapies for asthma and …
Gavi pledges $300 million for Ebola vaccines
December 12, 2014Manufacturing and Production, Sales and Marketing GAVI, GSK, GlaxoSmithKline, J&J, JJ, Merck, Vaccine, WHO, newlink
The global vaccines alliance Gavi has committed to buying Ebola vaccines as soon as the World Health Organization recommends one …
Ranbaxy launches J&J biosimilar in India
December 5, 2014Manufacturing and Production, Sales and Marketing CHMP, FDA, India, J&J, JJ, Ranbaxy, Remicade, nlem, nppa
Ranbaxy has launched the first biosimilar of Johnson & Johnson’s Remicade (infliximab) in India, marking the firm’s entry into monoclonal …
J&J announces ‘major commitment’ to Ebola effort
October 22, 2014Sales and Marketing Crucell, Ebola, J&J, JJ, Vaccine, bavarian, johnson, niaid
Johnson & Johnson will invest $200 million to accelerate and significantly expand the production of its Ebola vaccine programme. The …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
